Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors

Blood

Volumn 118, Issue 9, 2011, Pages 2551-2555

  Pronier, Elodie ^a,b   Almire, Carole ^a,b,c,d   Mokrani, Hayat ^a,b   Vasanthakumar, Aparna ^e   Simon, Audrey ^a,b   Da Costa Reis Monte Mor, Barbara ^a,b   Massé, Aline ^a,b   Le Couédic, Jean Pierre ^a,b   Pendino, Frédéric ^a,f   Carbonne, Bruno ^d   Larghero, Jérôme ^f   Ravanat, Jean Luc ^g   Casadevall, Nicole ^a,b,c,d   Bernard, Olivier A ^b,h   Droin, Nathalie ^a,b   Solary, Eric ^a,b   Godley, Lucy A ^e   Vainchenker, William ^a,b   Plo, Isabelle ^a,b   Delhommeau, François ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g CNRS   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; CD34 ANTIGEN; DNA;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; ERYTHROID CELL; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LEUKEMIA CELL LINE; MONOCYTE; MUTATION; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; UMBILICAL CORD BLOOD;

EID: 79960768558     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-324707     Document Type: Article

References (23)

1. Tahiliani M., Koh K.P., Shen Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930-935.
2. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129-1133.
3. Ficz G., Branco M.R., Seisenberger S., et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature. 2011;473(7347):398-402.
4. Tefferi A., Lim K.H., Abdel-Wahab O., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009;23(7):1343-1345.
5. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838-842.
6. Jankowska A.M., Szpurka H., Tiu R.V., et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009;113(25):6403-6410.
7. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
8. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144-147.
9. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567.
10. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-843.
11. Dupont S., Masse A., James C., et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110(3):1013- 1021.
12. Marie-Desvergne C., Maitre A., Bouchard M., Ravanat J.L., Viau C. Evaluation of DNA adducts, DNA and RNA oxidative lesions, and 3-hydroxybenzo(a)pyrene as biomarkers of DNA damage in lung following intravenous injection of the parent compound in rats. Chem Res Toxicol. 2010;23(7):1207-1214.
13. Song L., James S.R., Kazim L., Karpf A.R. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem. 2005;77(2):504-510. (Pubitemid 40116829)
14. Gilles L., Bluteau D., Boukour S., et al. MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood. 2009;114(19):4221-4232.
15. Delhommeau F., Dupont S., Tonetti C., et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109(1):71-77. (Pubitemid 46053046)
16. Kosmider O., Gelsi-Boyer V., Ciudad M., et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676-1681.
17. Kohlmann A., Grossmann V., Klein H.U., et al. Nextgeneration sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858-3865.
18. Schaub F.X., Looser R., Li S., et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003-2007.
19. Flach J., Dicker F., Schnittger S., Kohlmann A., Haferlach T., Haferlach C. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica. 2010;95(3):518-519.
20. Mullighan C.G. TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet. 2009;41(7):766-767.
21. Trowbridge J.J., Snow J.W., Kim J., Orkin S.H. DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell. 2009;5(4):442-449.
22. Bröske A.M., Vockentanz L., Kharazi S., et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet. 2009;41(11):1207-1215.
23. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.